New study uses MRI to catch pancreatic cancer early in High-Risk families

NCT ID NCT03250078

Recruiting now Diagnosis Sponsor: Nuvance Health Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is screening 200 people with a strong family history or genetic mutations linked to pancreatic cancer. Participants get an annual MRI/MRCP scan to look for early-stage cancer or pre-cancerous growths. They also donate blood samples to help develop a future blood test for pancreatic cancer. The goal is to detect the disease earlier, when it may be more treatable.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: MRI/MRCP with IV gadolinium contrast
What this could lead to: If successful, this could lead to a reliable screening method to catch pancreatic cancer early in high-risk individuals, potentially saving lives.
What could go wrong: This is an observational screening study, not a treatment trial. It may not prove that screening reduces deaths, and false positives could cause unnecessary worry or procedures.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANCREATIC NEOPLASMS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm pancreatic neoplasm malignant pancreatic neoplasm prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PANCREATIC NEOPLASMS

Contacts and locations

Locations

Nuvance Health
RECRUITING

Norwalk, Connecticut, 06856, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.